Living with eczema, the 56-year-old nurse has been receiving the drug on compassionate grounds since 2018.

But at a cost of about $20,000 a year on a private prescription - or $1600 a month - for the majority of people living with chronic skin conditions, the drug is financially out of reach.

On Thursday Ms Whittaker travelled to Canberra to urge the federal government to improve support and treatment access for Australians afflicted by severe eczema.

She was joined by "an army" of patients from NSW, Queensland, Victoria and Canberra, who want to see Dupixent subsidised through the Pharmaceutical Benefits Scheme.

IN OTHER NEWS

Ms Whittaker said she was sending an urgent an SOS to the federal government.

"For me this drug has been life changing allowing me to live a normal life and do the things most people take for granted," she said.

"I have the best skin I have had in my life using this drug.

"I am going there to ask that all Australians with moderate to severe skin conditions have the chance to try this drug and be able to experience the positive effects I have had, not only with my skin, but my mental and physical health as well."

An inherited chronic inflammatory skin condition that usually appears in early childhood, more than 27,000 Australians are estimated to be living with eczema.

While it can be mild and resolve after childhood, for others like Ms Whittaker the conditions can be debilitating - causing itching, pain and sleep deprivation.

"At its worst, my life just became stagnant," she said.

"I was in and out of hospital. I just spend my days bingeing on Netflix to distract myself and to just sit still. Anything else was just to painful. My life became very contracted."

Organised by Eczema Support Australia, Ms Whittaker said Thursday's meeting at Parliament House had been very positive.

"Hopefully we have opened their eyes to why this is such an important issue."